JP2003525909A5 - - Google Patents

Download PDF

Info

Publication number
JP2003525909A5
JP2003525909A5 JP2001564789A JP2001564789A JP2003525909A5 JP 2003525909 A5 JP2003525909 A5 JP 2003525909A5 JP 2001564789 A JP2001564789 A JP 2001564789A JP 2001564789 A JP2001564789 A JP 2001564789A JP 2003525909 A5 JP2003525909 A5 JP 2003525909A5
Authority
JP
Japan
Prior art keywords
adenovirus
virus
mos
group
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001564789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003525909A (ja
JP5118798B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/007194 external-priority patent/WO2001066137A1/en
Publication of JP2003525909A publication Critical patent/JP2003525909A/ja
Publication of JP2003525909A5 publication Critical patent/JP2003525909A5/ja
Application granted granted Critical
Publication of JP5118798B2 publication Critical patent/JP5118798B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001564789A 2000-03-07 2001-03-06 アデノウイルス製剤 Expired - Fee Related JP5118798B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18744000P 2000-03-07 2000-03-07
US60/187,440 2000-03-07
PCT/US2001/007194 WO2001066137A1 (en) 2000-03-07 2001-03-06 Adenovirus formulations

Publications (3)

Publication Number Publication Date
JP2003525909A JP2003525909A (ja) 2003-09-02
JP2003525909A5 true JP2003525909A5 (enExample) 2008-04-17
JP5118798B2 JP5118798B2 (ja) 2013-01-16

Family

ID=22688996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001564789A Expired - Fee Related JP5118798B2 (ja) 2000-03-07 2001-03-06 アデノウイルス製剤

Country Status (6)

Country Link
US (2) US20020041884A1 (enExample)
EP (2) EP2420247A1 (enExample)
JP (1) JP5118798B2 (enExample)
AU (1) AU4346101A (enExample)
CA (2) CA2799545A1 (enExample)
WO (1) WO2001066137A1 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
US20030232018A1 (en) * 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
EP1506287B1 (en) 2002-05-14 2007-04-25 Merck & Co., Inc. Methods of adenovirus purification
AU2003291526A1 (en) * 2002-11-15 2004-06-15 Genvec, Inc Coronary artery disease treatment
PL199642B1 (pl) * 2002-11-15 2008-10-31 Inst Immunologii I Terapii Do Preparat bakteriofagowy o podwyższonej trwałości oraz zastosowanie blokowego kopolimeru tlenku etylenu i tlenku propylenu
DK1585548T3 (en) * 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
WO2005052116A2 (en) * 2003-11-19 2005-06-09 Merck & Co., Inc. Preservative-containing virus formulations
ATE555127T1 (de) * 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
ES2932278T3 (es) * 2004-06-01 2023-01-17 Genzyme Corp Composiciones y métodos para prevenir la agregación del vector AAV
ATE412737T1 (de) 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
ES2987238T3 (es) 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
SI3988660T1 (sl) 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
CA2819236A1 (en) * 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
MX373096B (es) 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
EP2651439B1 (en) * 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
US20150044251A1 (en) * 2011-12-23 2015-02-12 Novartis Ag Stable compositions for immunising against staphylococcus aureus
AU2013228096B2 (en) * 2012-03-05 2017-07-13 Intravacc B.V. Methods and compositions for stabilizing dried biological materials
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
JP5845376B2 (ja) 2012-03-22 2016-01-20 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
PT2988780T (pt) 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN111514314A (zh) * 2013-09-19 2020-08-11 扬森疫苗与预防公司 改进的腺病毒配制品
EP3082769B1 (en) * 2013-12-19 2018-01-31 Janssen Vaccines & Prevention B.V. Improved formulations for virosomes
CN105267960A (zh) * 2014-06-13 2016-01-27 亚宝药业太原制药有限公司 一种重组腺病毒疫苗制剂及其制备方法
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
MX2018012094A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
CN110300591A (zh) * 2016-11-04 2019-10-01 百深公司 腺相关病毒制剂
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CA3045228C (en) 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
WO2018204677A1 (en) * 2017-05-04 2018-11-08 Epicentrx, Inc. Oncolytic adenovirus formulation
CA3062549A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624851A1 (en) * 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2019113202A1 (en) * 2017-12-05 2019-06-13 Applied Genetic Technologies Corporation Formulation optimization for viral particles
CN120227451A (zh) 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
MX2020013953A (es) 2018-07-11 2021-03-09 Takeda Pharmaceuticals Co Composiciones de virus adenoasociado (aav).
PE20211469A1 (es) 2018-11-13 2021-08-05 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
CN113613664B (zh) 2019-03-01 2025-11-18 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
JP7630443B2 (ja) * 2019-04-19 2025-02-17 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
EP4013436A1 (en) 2019-08-14 2022-06-22 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
CN113750227A (zh) * 2020-06-01 2021-12-07 康希诺生物股份公司 一种SARS-CoV-2疫苗
KR20230038496A (ko) 2020-07-13 2023-03-20 트랜스진 면역 억제의 치료
WO2022032104A1 (en) * 2020-08-07 2022-02-10 Janssen Biotech, Inc. Formulations for highly purified viral particles
IL291025B2 (en) * 2020-08-22 2026-03-01 Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte Pharmaceutical agent for inducing specific immunity against SARS-COV-2
US20240228548A9 (en) 2021-02-19 2024-07-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
IL291822B2 (en) * 2021-02-21 2026-04-01 Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte Using a rangefinder to recruit specific immunity against severe acute respiratory syndrome SARS-COV-2 for population vaccination (variants)
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
KR20240093931A (ko) * 2021-10-29 2024-06-24 에이지씨 가부시키가이샤 세포 첨가용 조성물
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CN119654339A (zh) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 包含表面活性蛋白-d和tnfsf成员的融合蛋白
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스
WO2025045082A1 (zh) * 2023-09-01 2025-03-06 康霖生物科技（杭州）有限公司 一种缓冲系统及其相应液体制剂及其用途
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2088992A (en) 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
JP4386965B2 (ja) * 1996-04-26 2009-12-16 メルク エンド カンパニー インコーポレーテッド Ｄｎａワクチン製剤
AU737243B2 (en) * 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
WO1998035562A1 (en) 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations
CA2995542A1 (en) * 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
KR100918187B1 (ko) * 1998-02-17 2009-09-22 쉐링 코포레이션 바이러스를 포함하는 조성물 및 바이러스 제제의 농축방법
BR9801328A (pt) 1998-03-09 1999-10-05 Cardio Sistemas Comercial E In Equipamento multi-funcional para diagnostico e monitoração da atividade elétrica/cardìaca
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ATE413188T1 (de) * 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
KR101492396B1 (ko) 2014-09-11 2015-02-13 주식회사 우심시스템 어레이형 잉크 카트리지

Similar Documents

Publication Publication Date Title
CA2399321A1 (en) Adenovirus formulations
US7456009B2 (en) Adenovirus formulations
JP6817370B2 (ja) 弱毒生ウイルス組成物
Roderfeld et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase‐9 mutants in mice
ES2258970T3 (es) Vectores y vacunas viricas a base de adenovirus porcinos recombinados.
JP4709545B2 (ja) 修飾された低分子干渉ｒｎａ分子および使用方法
JP2021523916A (ja) メッセンジャーｒｎａの皮下送達
US8138161B2 (en) Modified small interfering RNA molecules and methods of use
RU2003137561A (ru) 4-замещенные нуклеозиды
WO2000077216A3 (en) Porcine circovirus vaccine in recombinant poxvirus
JP2007224052A (ja) 因子ｉｘ用処方
WO2007047146A3 (en) Inhibitors of viral replication
JP2003505482A (ja) ロタウイルスワクチン調合物
JP4651942B2 (ja) Ｅｂｖ及びｋｈｓｖ感染並びにそれに伴う異常細胞増殖の治療
JP2020503017A5 (enExample)
ATE428408T1 (de) Pharmazeutische zusammensetzung mit fenofibrat und herstellungsverfahren dafür
JPS6051112A (ja) 抗ウイルス配合組成物
AU2002303503B2 (en) Foot and mouth disease virus vaccine
ES2381266T3 (es) Terapias de combinación de L-FMAU para el tratamiento de la infección por el virus de la hepatitis B
CN116549642A (zh) p23蛋白抑制剂用于抑制和/或杀灭病毒的产品
EP2747777A2 (en) Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures
US20040033239A1 (en) Adenovirus formulations
AU738472B2 (en) Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection
AU2006202389B2 (en) Adenovirus formulations
JP2022551107A (ja) アデノウイルスベクターおよびその使用